ArticleMedical oncology (Northwood, London, England)2025
Antimetastatic effects of chamuangone-enriched extract in breast cancer lung metastasis: in vitro and in vivo evidence.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Breast cancer lung metastasis (BCLM) is the most lethal form of breast cancer (BC). Current treatments are costly and often associated with severe side effects, emphasizing the need for alternative therapies. A chamuangone-enriched extract (CEE), quantitatively standardized by HPLC to contain 73.0 ± 2.0% w/w chamuangone, was developed from the leaves of the Thai vegetable Garcinia cowa and evaluated for its anticancer efficacy. Both in vitro and in vivo studies were conducted using MCF-7 cells in a human breast cancer xenograft model. Histopathological examination of the tumor and lungs, as well as expression of BCLM markers (ER, PR, Ki-67, CD44, IL-6, TNF-α, VEGFA, E-cadherin, and N-cadherin) expression in the tumor and lungs were evaluated through immunohistochemistry. In vitro studies, CEE at a concentration of 10 µg/mL inhibited MCF-7 cell growth and migration, induced apoptosis, and significantly modulated apoptotic and inflammatory markers (p53 and Bcl-2, MMP-2, MMP-9, IL-6, and TNF-α) in MCF-7 cells. In vivo studies, CEE (100 mg/kg bodyweight) significantly inhibited tumor growth and decreased the expressions of BCLM markers in tumor and lung tissues, resulting in the suppression of BC and metastasis. These results support the potential medicinal and protective use of CEE as a functional ingredient for mitigating the devastating effects of BC and BCLM.
Indexed as
Identifiers
41085837What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.